Mitsui Fumihiko, Dobashi Yoh, Imoto Issei, Inazawa Johji, Kono Koji, Fujii Hideki, Ooi Akishi
Department of Pathology, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Mod Pathol. 2007 Jun;20(6):622-31. doi: 10.1038/modpathol.3800777. Epub 2007 Apr 13.
This study was conducted to assess the frequencies of protein overexpression and gene amplification of Myc and to identify the mechanisms of Myc gene amplification, especially with regards to its possible coamplification with ERBB2 or EGFR in gastric adenocarcinomas. By immunohistochemical analysis of a total of 300 formalin-fixed and paraffin-embedded gastric adenocarcinomas, the nuclear overexpression of MYC was found in 47 tumors (16%). A fluorescence in situ hybridization (FISH) analysis revealed that nine (19%) of the 47 tumors with protein overexpression had cancer cells with high levels of Myc amplification, whereas only seven (6%) of the 122 tumors without protein overexpression showed high-level Myc gene amplification. Such Myc amplification was significantly correlated with positive nuclear protein overexpression. The coamplification of ERBB2 or EGFR with Myc that was found in six and four cases, respectively, is believed to be non-incidental because those frequencies were significantly higher than the individual frequencies observed for the total examined cases (ERBB2: 7%; EGFR: 4%). The high levels of gene amplification of these three genes, as visualized by FISH, could be broadly classified into two typical types, namely, 'multiple scattered signals' and 'large clustered signals'. Using two-color FISH, the coexistence of coamplified Myc and ERBB2, or Myc and EGFR, within single nuclei in various combinations of amplification types and copy numbers, could be ascertained in all nine cases, including one in which the synchronous 'multiple scattered type' coamplification of Myc and ERBB2 was observed. In three tumors, coamplification of ERBB2 and EGFR was found; however, ERBB2- and EGFR-amplified cell populations were separate and mutually exclusive. We propose that the non-incidental coamplification of Myc and either ERBB2 or EGFR occurred through translocation and subsequent rearrangement.
本研究旨在评估Myc蛋白过表达和基因扩增的频率,并确定Myc基因扩增的机制,特别是其在胃腺癌中与ERBB2或EGFR可能的共扩增情况。通过对总共300例福尔马林固定石蜡包埋的胃腺癌进行免疫组织化学分析,发现47例肿瘤(16%)中存在MYC核过表达。荧光原位杂交(FISH)分析显示,47例蛋白过表达的肿瘤中有9例(19%)癌细胞存在高水平的Myc扩增,而122例无蛋白过表达的肿瘤中只有7例(6%)显示高水平的Myc基因扩增。这种Myc扩增与核蛋白阳性过表达显著相关。分别在6例和4例中发现的ERBB2或EGFR与Myc的共扩增被认为并非偶然,因为这些频率显著高于所有检查病例中观察到的各自频率(ERBB2:7%;EGFR:4%)。通过FISH观察到的这三个基因的高水平基因扩增可大致分为两种典型类型,即“多个散在信号”和“大的聚集信号”。使用双色FISH,在所有9例中都可以确定共扩增的Myc和ERBB2或Myc和EGFR在单个细胞核内以各种扩增类型和拷贝数组合共存,其中包括1例观察到Myc和ERBB2同步“多个散在型”共扩增的病例。在3例肿瘤中发现了ERBB2和EGFR的共扩增;然而,ERBB2扩增和EGFR扩增的细胞群体是分开的且相互排斥。我们提出,Myc与ERBB2或EGFR的非偶然共扩增是通过易位和随后的重排发生的。